Advancements in Targeted Therapies for ER Positive Breast Cancer

This chapter explores L-acestrin as the sole commercial CERD for estrogen-positive, HER2-negative metastatic breast cancer, detailing its clinical efficacy and survival benefits. It also highlights a promising clinical trial with lazofoxifene and abemaciclib, stressing the need for shared decision-making in evolving treatment options.